首頁 > 市場調查報告書 > 製藥

呼吸器

呼吸治療市場規模、佔有率、成長分析（按藥物類別、疾病類型、給藥途徑、分銷管道、地區、產業預測，2025-2032 年）

市場調查報告書

商品編碼

1755445

呼吸治療市場規模、佔有率、成長分析（按藥物類別、疾病類型、給藥途徑、分銷管道、地區、產業預測，2025-2032 年）

Respiratory Drugs Market Size, Share, and Growth Analysis, By Drug Class (Short-Acting Beta2-Agonists, Long-Acting Beta2-Agonists ), By Disease Type, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日期: 2025年06月16日 | 出版商:

SkyQuest | 英文 197 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計 2023 年全球呼吸藥物市場價值將達到 37 億美元，並從 2024 年的 40.1 億美元成長到 2032 年的 77.1 億美元，預測期內（2025-2032 年）的複合年成長率為 8.5%。

受全球呼吸系統疾病激增的推動，預計2025年至2032年間，呼吸系統藥物市場將大幅成長。由於空氣污染加劇、過敏原暴露增加以及人們對呼吸系統疾病認知的提高等因素，診斷和治療率正在上升。在高所得國家，超過70%的慢性阻塞性肺病（COPD）病例與吸菸有關，而在中低收入國家，這一比例為30%至40%，家庭空氣污染也扮演關鍵角色。吸菸仍然是導致COPD、肺癌和呼吸道感染疾病等呼吸系統疾病的主要原因，因為它會長期損害肺功能。這凸顯了對有效呼吸系統藥物治療這些常見疾病的迫切需求。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）
  主要企業簡介
  - 葛蘭素史克公司（GSK）（英國）
  - 阿斯特捷利康公司（英國）
  - 勃林格殷格翰國際有限公司（德國）
  - 默克公司（美國）
  - 諾華公司（瑞士）
  - F. Hoffmann-La Roche Ltd.（瑞士）
  - 梯瓦製藥工業股份有限公司（以色列）
  - 賽諾菲（法國）
  - 輝瑞公司（美國）
  - 艾伯維公司（美國）
  - Vertex Pharmaceuticals Incorporated（美國）
  - 邁蘭製藥公司（美國）
  - 太陽製藥工業有限公司（印度）
  - 魯賓有限公司（印度）
  - 西普拉有限公司（印度）
  - Chiesi Farmaceutici SpA（義大利）
  - 住友大日本製藥有限公司（日本）
  - 貝希姆科製藥股份有限公司（孟加拉）
  - Respirerx Pharmaceuticals Inc.（美國）
  - Viatris Inc.（美國）

結論和建議

簡介目錄

Product Code: SQMIG35I2377

Global Respiratory Drugs Market size was valued at USD 3.7 billion in 2023 and is poised to grow from USD 4.01 billion in 2024 to USD 7.71 billion by 2032, growing at a CAGR of 8.5% during the forecast period (2025-2032).

The respiratory drugs market is poised for significant growth between 2025 and 2032, driven by a surge in respiratory disorders globally. Factors such as rising air pollution, increased allergen exposure, and heightened awareness of respiratory diseases have led to greater diagnosis and treatment rates. In high-income countries, over 70% of Chronic Obstructive Pulmonary Disease (COPD) cases are attributed to tobacco smoking, while in low- and middle-income countries, this figure is 30-40%, with household air pollution also playing a critical role. Smoking remains a leading cause of respiratory issues, including COPD, lung cancer, and respiratory infections, as it inflicts long-term damage on lung function. This underscores the urgent need for effective respiratory therapies to manage these prevalent conditions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Respiratory Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Respiratory Drugs Market Segments Analysis

Global Respiratory Drugs Market is segmented by Drug Class, Disease Type, Route of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Short-Acting Beta2-Agonists (SABA), Long-Acting Beta2-Agonists (LABA), Inhaled Corticosteroids (ICS), Anticholinergics, Antihistamines, Vasodilators, Combination Drugs and Others. Based on Disease Type, the market is segmented into Asthma, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Pleural Effusion and Others. Based on Route of Administration, the market is segmented into Inhalation, Enteral and Parenteral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Respiratory Drugs Market

The Global Respiratory Drugs market is significantly driven by advancements in artificial intelligence, which are transforming the discovery process of new respiratory medications. By swiftly analyzing extensive datasets, AI technologies can pinpoint potential compounds and biological targets with remarkable speed and efficiency. Machine learning algorithms can effectively simulate the interactions between drug candidates and human biology, thereby streamlining the preclinical phase and accelerating overall development timelines. Notably, AI platforms such as BenevolentAI and Atomwise are being harnessed to create groundbreaking therapies for conditions like asthma and chronic obstructive pulmonary disease (COPD), empowering pharmaceutical companies to enhance innovation while minimizing research and development costs.

Restraints in the Global Respiratory Drugs Market

The Global Respiratory Drugs market faces certain constraints, particularly in the integration of artificial intelligence into drug development. This process demands a significant investment in computational infrastructure, skilled workforce, and ongoing software enhancements, which can be financially burdensome for smaller pharmaceutical firms or those operating in developing regions. Additionally, the challenge of incorporating AI tools into existing legacy systems often results in technical and logistical difficulties, hindering the progress of digital transformation within research and development efforts for respiratory medications. These factors collectively pose considerable obstacles to the advancement and efficiency of respiratory drug innovation in the market.

Market Trends of the Global Respiratory Drugs Market

The Global Respiratory Drugs market is increasingly influenced by the rise of AI-enabled smart inhalers, which are transforming respiratory care. These innovative devices, such as Propeller Health's inhaler sensors, track medication adherence, monitor symptoms, and offer real-time feedback to both patients and healthcare providers. By ensuring proper inhaler techniques and minimizing missed doses, these technologies enhance patient engagement and adherence to treatment protocols. Furthermore, the data generated facilitates personalized treatment plans, thereby improving clinical outcomes. As advancements in AI and digital health technology progress, the integration of smart inhalers is expected to drive substantial growth in the respiratory drugs sector, meeting the rising demand for more effective, personalized healthcare solutions.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Respiratory Drugs Market Size by Drug Class & CAGR (2025-2032)

Market Overview
Short-Acting Beta2-Agonists (SABA)
Long-Acting Beta2-Agonists (LABA)
Inhaled Corticosteroids (ICS)
Anticholinergics
Antihistamines
Vasodilators
Combination Drugs
Others

Global Respiratory Drugs Market Size by Disease Type & CAGR (2025-2032)

Market Overview
Asthma
Chronic Bronchitis
Chronic Obstructive Pulmonary Disease (COPD)
Pleural Effusion
Others

Global Respiratory Drugs Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Inhalation
Enteral
Parenteral

Global Respiratory Drugs Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Respiratory Drugs Market Size & CAGR (2025-2032)

North America (Drug Class, Disease Type, Route of Administration, Distribution Channel)
- US
- Canada
Europe (Drug Class, Disease Type, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Disease Type, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Disease Type, Route of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Disease Type, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

GlaxoSmithKline Plc (GSK) (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Incorporated (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chiesi Farmaceutici S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sumitomo Dainippon Pharma Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beximco Pharmaceuticals Ltd. (Bangladesh)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Respirerx Pharmaceuticals Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments